Choose your Region

Are you sure you want to proceed?

You will be leaving the Cook Medical website that you were viewing and going to a Cook Medical website for another region or country. Not all products are approved in all regulatory jurisdictions. The product information on these websites is intended only for licensed physicians and healthcare professionals.

September 12th, 2020

Prediction model presented at CIRSE conference highlights transparency in patient outcomes with Zilver® PTX®

Bloomington, Ind. – At this year’s Cardiovascular and Interventional Radiological Society of Europe (CIRSE) conference, Michael D. Dake, MD, presented a prediction model for treatment outcomes for patients treated with Zilver PTX. The model includes data generated from more than 2,200 patients and provides increased transparency regarding the effects that patients and physicians can expect when using Zilver PTX, Cook Medical’s paclitaxel-coated drug-eluting stent (DES).

Zilver PTX, Cook Medical’s drug-eluting stent

Dr. Dake is the senior vice president of health sciences at the University of Arizona, Tucson,
and is president-elect of the Society of Interventional Radiology Executive Council. He worked with Cook Research, Inc., to create this prediction model to determine the impact of patient and lesion factors on freedom from target lesion revascularization (ffTLR) for patients who are candidates for Zilver PTX treatment.

The prediction model was developed by compiling patient factors, lesion characteristics, and total lesion revascularization (TLR) rates from five global studies of the Zilver PTX clinical program. The model was based on data from five different studies and more than 2,200 patients. When creating this model,15 different patient factors were taken into account, including sex, age, lesion length, severity of calcification, diabetes, and prior interventions.

“We are sharing this prediction model and its associated outcomes to continue being transparent with data,” said Mark Breedlove, vice president of Cook Medical’s vascular division. “We hope patients and physicians can use this model to be more informed about Zilver PTX in choosing the best treatment option. This prediction model allows clinicians and patients to have better conversations around expected outcomes with Zilver PTX.”

The prediction model that Dr. Dake presented has been accepted by CardioVascular and Interventional Radiology (CVIR), a peer-reviewed journal, and will be published soon.

If you have questions about Zilver PTX, please contact us at Information on the Zilver PTX prediction model is available at

Dr. Michael Dake is a paid consultant for Cook Medical.

About Cook Medical
Since 1963, Cook Medical has been inventing, manufacturing and delivering a unique portfolio of medical devices to healthcare systems around the world. We work closely with physicians to develop technologies that improve patients’ lives. Because we remain family owned, we have the freedom to focus on what we care about: patients, our employees and our communities. Find out more at, and for the latest news, follow us on TwitterFacebook and LinkedIn.